Hansa Biopharma AB Sustainability Reports
Hansa Biopharma AB is a commercial-stage biopharmaceutical company that develops innovative immunomodulatory treatments for rare immunological conditions. Its proprietary enzyme technology platform targets and inactivates IgG antibodies to facilitate organ transplantation and treat acute autoimmune diseases.
Sector: Manufacturing
Country: Sweden
Exchange: Nasdaq Stockholm
LEI: 549300LLEO25ZJJ3NT91
FIGI: BBG001SMMNF7
10 reports from 2018 to 2025
